Cargando…

Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment

Detalles Bibliográficos
Autores principales:	Smets, I., Reyes, S., Baker, D., Giovannoni, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897403/ https://www.ncbi.nlm.nih.gov/pubmed/33636615 http://dx.doi.org/10.1016/j.msard.2021.102851

Ejemplares similares

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
por: Conte, William L
Publicado: (2020)

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
por: Lucchini, Matteo, et al.
Publicado: (2020)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Need to promote healthy lifestyle as primary prevention to the COVID-19 and to improve the immune response to vaccines
por: De la Cámara, Miguel A, et al.
Publicado: (2021)

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
por: Weberpals, Janick, et al.
Publicado: (2022)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

Management of bronchial rupture after blunt chest trauma in children
por: Wu, Yu-Hao, et al.
Publicado: (2019)

Blunting COVID-19's negative impact: Lessons from Israel's vaccination campaign
por: Tsigaris, Panagiotis, et al.
Publicado: (2021)

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
por: Thornton, Jeanine Rempe, et al.
Publicado: (2020)

Immune response after vaccination using inactivated vaccine for coronavirus disease 2019
por: Sun, Ya, et al.
Publicado: (2023)

Ocrelizumab/tozinameran interaction: Impaired vaccine response: 4 case reports
Publicado: (2021)

Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
por: Pompsch, Mosche, et al.
Publicado: (2021)

Specific Biological Diagnoses Are Needed to Determine the Durability of Pertussis Vaccine–Induced Immunity
por: Guiso, Nicole
Publicado: (2012)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

Vaccinated Individuals With Prior COVID-19 Have Lower Risk of Incident SARS-CoV-2 Infection When Compared With Vaccinated Individuals Without Prior Infection
por: Kojima, N, et al.
Publicado: (2022)

A Case of Vaping-associated Pulmonary Illness in South America: Highlighting the Need for Awareness and Surveillance Programs in the Region
por: Boloña, Enrique, et al.
Publicado: (2020)

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
por: Thevarajan, Irani, et al.
Publicado: (2020)

Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis
por: Ciardi, Maria R, et al.
Publicado: (2018)

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
por: Brill, Livnat, et al.
Publicado: (2022)

Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine
por: Herrera-Comoglio, Raquel, et al.
Publicado: (2022)

Ocular Hypotony after Cataract Surgery in an Eye with Prior Trabeculectomy
por: Chung, Jae Keun, et al.
Publicado: (2020)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Ocrelizumab-Induced Severe Colitis
por: Lee, Hsing Hwa, et al.
Publicado: (2020)

Pick your prior: scepticism about sceptical prior beliefs
por: de Grooth, Harm-Jan, et al.
Publicado: (2021)

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
por: Katz, J.D., et al.
Publicado: (2022)

Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response
por: Boziki, Marina, et al.
Publicado: (2022)

Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection
por: Stellini, Roberto, et al.
Publicado: (2021)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis
por: Keebayoon, Amnuay, et al.
Publicado: (2023)

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab
por: Nytrova, Petra, et al.
Publicado: (2023)

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm
por: Magee, Laura A, et al.
Publicado: (2021)

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
por: Collier, Ai-ris Y., et al.
Publicado: (2021)

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9u4lbtqja8blh5fnfplk9lh21i